Heidelberg Pharma

At this time, Heidelberg Pharma is not offering Expanded Access for its investigational products. The Company believes that investigational products should be studied within the context of a clinical trial and encourage patients to participate in a clinical trial wherever possible. As such, participating in Heidelberg Pharma's clinical trial is the most appropriate way to access pamlectabart tismanitin (HDP-101) at this stage of clinical development. Information about the clinical trials, including eligibility criteria and locations, is available at www.clinicaltrials.gov.